S.M. Kirov Military Medical Academy, Akademika Lebedeva str. 6
Brief summary
Due to the continuing increase in the incidence of liver cirrhosis, the problem of finding new drugs for the treatment of toxic hepatitis, fibrosis and cirrhosis of the liver remains relevant. In the course of a clinical study, the effectiveness of the use of inosine glycyl-cysteinyl-glutamate disodium for the prevention of liver fibrosis in toxic hepatitis was evaluated. Results obtained indicate the expediency of using inosine glycyl-cysteinyl-glutamate disodium in the treatment of toxic hepatitis and liver fibrosis.
1. Roth, G.A. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. / G.A. Roth, D. Abate, K.H. Abate et al. // Lancet. 2018; 392: S. 1736-1788
3. Halutin, D.A. Terapevticheskii effekt novih neiropeptidov i gepatoprotektora moliksan pri ostrih otravleniyah etanolom/D.A. Halutin, A.A. Hovpachev, A.N. Grebenuk, V.L. Reinuk, A.E. Antyshevich, A.A. Kolobov//Toksikologicheskii vestnik. 2015. 2. S. 10-17.
4. Belyakin, S.A. Smertnost ot cirroza pecheni kak indikator yrovnya potrebleniya alkogolya v popylyacii/S.A. Belyakin, A. N. Bobrov//Vestnik Rossiiskoi voenno-medicinskoi akademii. 2009. T. 3. S. 189-194.
5. Kalinin, A.V. Alkogolnaya bolezn pecheni/A.V. Kalinin, A.I. Hazanov// Klinicheskie lekcii po gastroenterologii i gepatologii. - M., 2002. - S.127-163.
7. Maev, I. V. Alkogolnaya bolezn pecheni: sovremennoe sostoyanie problemi/I.V. Maev, D. T. Abdyrahmanov, D. N. Andreev, D. T. Dicheva//Terapevticheskii arhiv. 2014. No 4. S. 108-116.
8. Barishnikova, H.V. Alkogolnaya bolezn pecheni: osobennosti diagnostiki i lecheniya/ H.V. Barishnikova, L.N. Beloysova//Gastroenterologiya. Prilojenie k jyrnaly Consilium Medicum. 2014. No 2. S. 16-18.
9. Bytorova, L.I. Gepatoprotektivnaya terapiya jirovoi bolezni pecheni nealkogolnogo i alkogolnogo geneza/ L.I. Bytorova, M.A. Kalashnikova, N.G. Krainikova, M.A. Osadchyk, T.E. Plavnik, G.M. Tokmylina//Gastroenterologiya 2016; 2 (34): S 12-21.
10. Shiff, U.R. Alkogolnie, lekarstvennie, geneticheskie i metabolicheskie zabolevaniya/U.R. Shiff, M.F. Sorrel, Y.S. Meddrei/pod red. N.A. Myhina, D.T. Abdyrahmanova, E.E. Byrnevicha i dr.//M.: GEOTAR-Media, 2011.
13. Iredale, J. P. Models of liver fibrosis, exploring the dynamic nature of inflammation and repair in a solid organ/ J. P. Iredale // J.Clin. Invest. 2007; 117(3): S. 539-548.
14. Parsons, C.J. Molecular mechanisms of hepatic fibrogenesis/ C.J. Parsons, M. Takashima, R.A. Rippe // J. Gastroenterol Hepatol. 2007; 22 (1); S.79-84.
15. Kyrisheva, M. A. Fibroz pecheni: proshloe, nastoyashee, bydyshee / M. A. Kyrisheva // Ryssykii medicinskii jyrnal 2010. 28. S.1713-1717.
16. Severov, M.V. Obratimost fibroza i cirroza pecheni pri HCV- infekcii/ M.V. Severov// Gepatologicheskii forym 2008; 1: S.2-6.
18. Abdyrahmanov, D. T. Protivovirysnaya terapiya i regressiya fibroza pecheni pri hronicheskom gepatite V/D.T. Abdyrahmanov// Rossiiskii jyrnal gastroenter. gepatol. koloproktol. 2010. 1. S. 14-20.
31. Festi, D. Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance/D. Festi, A. Colecchia, T. Sacco, M. Bondi, E. Roda// Obes Rev. - 2004. - No 5(1). - R. 27-42.
32. Aprosina, Z.G. Aytoimmynnii gepatit/Z.G. Aprosina// Prakticheskaya gepatologiya. Pod red. N.A. Myhina. - M., 2004.- S.101-105.
34. Orlov, U.V. Sovremennoe sostoyanie problemi lecheniya toksicheskih gepatitov i fibrozov pecheni/U.V. Orlov, D.A. Sinyachkin, U.Sh. Halimov, A.E. Antyshevich// Biomedicinskii jyrnal Medline.ru, tom 18, ST.33, s 488-510, 18 oktyabrya 2017 g.
35. Bygaev, P.A. Sravnitelnaya effektivnost moliksana i glytoksima na modeli toksicheskogo porajeniya pecheni protivotyberkyleznimi preparatami/P.A. Bygaev, V.A Basharin, A.E. Antyshevich//Obzori po klinicheskoi farmakologii i lekarstvennoi terapii. 2019. - T. 17. - 2. - S. 49-54. https://doi.org/10.7816/ RCF17249-54